Immuneering Corp
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
IMRX$3.68+9.2%Stored close · as of Nov 6, 2026
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-15.
0001790340-26-000057
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-05.
0001790340-26-000091
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 132 previous paragraphs and 143 current paragraphs.
103 unchanged; 23 reworded; 12 added; 6 removed; 0 previous and 5 current paragraphs rearranged.
Tables are not compared: 4 previous and 7 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (12)
Current report
In June 2026, we announced further positive interim response and safety data from the Phase 2 mGnP Arm. We announced that, as of a cutoff date of April 24, 2026 (the “Cutoff Date”), 17.3 month median overall survival (“mOS”) was observed in the intent-to-treat population of 55 patients dosed at the 320 mg once-daily dose level of atebimetinib in combination with mGnP (the “320 mg ITT Population”), with median follow-up time of 11.6 months. The standard of care (described below) reported a 8.5 month mOS. As of the Cutoff Date, the median progression free survival ("mPFS") of the 320 mg ITT Population was 8.3 months. As of the Cutoff Date, in response evaluable patients from the 320 mg ITT Population, a 36% (18/50 patients) overall response rate ("ORR") and 82% (41/50 patients) disease control rate ("DCR") was observed. Additionally, as of the Cutoff Date, among the subset of patients from the 320 mg ITT Population for which sufficient weight stability data was available, 84% of such patients either gained weight or else were within 5% of original recorded baseline weight. The reported data included patients from same patient cohort (N=34) as we previously reported in January 2026, as well as an additional 21 patients, together comprising the full 320 mg ITT Population. The estimates of (and other references to) standard of care set forth above with respect to mOS data were reported out directly from the publicly available third-party MPACT pivotal trial data for gemcitabine/nab-paclitaxel. Our Phase 1/2a clinical trial of atebimetinib does not include a head-to-head comparison against any other agents, and caution should be exercised when comparing data across trials.
Current report
We also announced that, as of the Cutoff Date, atebimetinib in combination with mGnP continued to be generally well tolerated. As of the Cutoff Date, Grade ≥ 3 treatment-emergent adverse events (“TEAEs”) observed in 10% or greater of patients in the 320 mg ITT Population consisted of Anemia (nine patients or 16%) and Neutropenia (ten patients or 18%). Grade ≥ 3 TEAEs observed in less than 10% of patients in the 320 mg ITT Population included Rash (5%), Fatigue (2%), Vomiting (2%), and Oedema Peripheral (2%). No Grade 5 TEAEs were observed in this patient population and no new safety signals were identified.
Current report
•in the fourth quarter of 2026, additional pre-clinical data of atebimetinib in combination with anti-PD-1 in non-small cell lung cancer;
Current report
•in mid-2027, beginning IND-enabling studies for our next DCI product candidate program; and
Current report
•in mid-2028, providing a topline data readout from the MAPKeeper 301 trial.
Current report
Components of Our Results of Operations
Current report
Comparison of the Six Months Ended June 30, 2026 and 2025
Current report
The following table summarizes the components of research and development expenses for the periods indicated:
Current report
Research and development expenses increased by approximately $2.7 million, or 12.4%, to approximately $24.6 million for the six months ended June 30, 2026, as compared to approximately $21.9 million for the six months ended June 30, 2025. The increase of approximately $2.7 million was primarily due to an increase in direct research and development expenses of $1.8 million, driven by a $1.9 million increase in expenses related to the initiation of the MAPKeeper 301 trial, in addition to increased preclinical spend of approximately $1.8 million. This was offset by a decrease of approximately $1.9 million in expenses related to the envometinib program, due to the Company's prioritization of the atebimetinib program. The overall increase to research and development expenses was also driven by an increase of approximately $0.9 million related to indirect research and development expenses. Indirect expenses were driven by an approximate $1.0 million increase associated with employee-related costs, offset by a minor decrease in stock-based compensation expense, depreciation/amortization, and facilities and other expenses, in the aggregate.
Current report
The following table summarizes the components of general and administrative expenses for the periods indicated:
Current report
General and administrative expenses increased by approximately $1.4 million, or 16.6%, to approximately $9.7 million for the six months ended June 30, 2026, as compared to approximately $8.3 million for the six months ended June 30, 2025. The increase of approximately $1.4 million was due to a $0.9 million increase in employee-related costs, an increase in professional fees incurred for accounting, auditing, legal and tax services of approximately $0.3 million, increased other expenses of approximately $0.2 million, primarily consisting of software costs supporting the general and administrative functions, and increased stock-based compensation costs of approximately $0.1 million.
Current report
Amortization of Intangible Asset
Removed paragraphs (6)
Previous report
Research and Development
Previous report
General and Administrative
Previous report
Other income (expense)
Previous report
Research and Development
Previous report
General and Administrative
Previous report
Other Income (Expense)
Reworded paragraphs (23)
Previous wording
Our lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. We are currently recruiting patients for a Phase 3 clinical trial of atebimetinib, which we call the MAPKeeper 301 trial, to evaluate atebimetinib in combination with mGnP in first-line pancreatic cancer patients. We expect to dose the first patient in the MAPKeeper 301 trial in mid-2026.
Current wording
Our lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. We are currently conducting a Phase 3 clinical trial of atebimetinib, which we call the MAPKeeper 301 trial, to evaluate atebimetinib in combination with mGnP in first-line pancreatic cancer patients. We dosed the first patient in the MAPKeeper 301 trial in June 2026.
Previous wording
MAPKeeper 301 is designed as a global Phase 3 registrational trial that will evaluate atebimetinib (320 mg once-daily) in combination with mGnP, compared to standard of care GnP alone, in first-line metastatic PDAC. The primary endpoint of MAPKeeper 301 is overall survival, and secondary endpoints include progression-free survival, overall response rate, disease control rate, and quality of life measurements. We plan to enroll a total of approximately 510 patients in MAPKeeper 301, divided equally across the two arms.
Current wording
MAPKeeper 301 is a global Phase 3 registrational trial to evaluate atebimetinib (320 mg once-daily) in combination with mGnP, compared to standard of care GnP alone, in first-line metastatic PDAC. The primary endpoint of MAPKeeper 301 is overall survival, and secondary endpoints include progression-free survival, overall response rate, disease control rate, and quality of life measurements. We plan to enroll a total of approximately 510 patients in MAPKeeper 301, divided equally across the two arms.
Previous wording
In January 2026, we announced positive interim response and safety data from our ongoing Phase 2a clinical trial arm evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients, which is part of our ongoing Phase 1/2a clinical trial of atebimetinib in patients with advanced solid tumors.
Current wording
In January 2026, we announced positive interim response and safety data from our ongoing Phase 2a clinical trial arm evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients (the "Phase 2 mGnP Arm"), which is part of our ongoing Phase 1/2a clinical trial of atebimetinib in patients with advanced solid tumors.
Previous wording
We expect the following additional near-term milestones related to atebimetinib: announcing further updated survival and safety data from an expanded cohort of approximately 55 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in our ongoing Phase 1/2a clinical trial, in the second quarter of 2026; and dosing the first patient in a planned clinical trial of atebimetinib in combination with Libtayo® in non-small cell lung cancer patients, in the second half of 2026.
Current wording
We expect the following anticipated milestones:
Previous wording
We did not sell any shares of common stock under the 2022 ATM Program during the three months ended March 31, 2026. We sold 4,836,804 shares of common stock under the 2022 ATM Program, at a weighted average price per share of $2.95, for aggregate gross proceeds of $14.2 million ($13.7 million net of offering expenses) during the three months ended March 31, 2025. We did not sell any shares of common stock under the 2025 ATM Program during the three months ended March 31, 2026 or March 31, 2025.
Current wording
We did not sell any shares of common stock under the 2022 ATM Program during the three and six months ended June 30, 2026. We sold 4,836,804 shares of common stock under the 2022 ATM Program, at a weighted average price per share of $2.95, for aggregate gross proceeds of $14.2 million ($13.7 million net of offering expenses) during the three and six months ended June 30, 2025. We did not sell any shares of common stock under the 2025 ATM Program during the three and six months ended June 30, 2026 or June 30, 2025, respectively.
Previous wording
Since our inception, we have had significant annual operating losses. Our net loss was approximately $13.5 million for the three months ended March 31, 2026 and approximately $56.0 million for the year ended December 31, 2025. As of March 31, 2026, we had an accumulated deficit of approximately $293.8 million and approximately $198.6 million in cash, cash equivalents and marketable securities.
Current wording
Since our inception, we have had significant annual operating losses. Our net loss was approximately $30.7 million for the six months ended June 30, 2026 and approximately $56.0 million for the year ended December 31, 2025. As of June 30, 2026, we had an accumulated deficit of approximately $311.1 million and approximately $182.7 million in cash, cash equivalents and marketable securities.
Previous wording
As of May 15, 2026, the issuance date of the interim condensed consolidated financial statements for the three-months ended March 31, 2026 included elsewhere in this Quarterly Report on Form 10-Q, based on our recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future and the need to raise additional capital to finance future operations, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our development activities and other operations into 2029. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured.
Current wording
As of August 5, 2026, the issuance date of the interim condensed consolidated financial statements for the three and six-months ended June 30, 2026 included elsewhere in this Quarterly Report on Form 10-Q, based on our recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future and the need to raise additional capital to finance future operations, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our development activities and other operations into 2029. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured.
Previous wording
Research and development expenses decreased by approximately $0.8 million, or 7.2%, to approximately $10.6 million for the three months ended March 31, 2026, as compared to approximately $11.5 million for the three months ended March 31, 2025. The decrease of approximately $0.8 million was primarily due to a decrease in direct costs of $1.0 million, primarily driven by a $1.6 million decrease in expenses related to the envometinib program due to the Company's prioritization of the atebimetinib program, in addition to a $0.2 million decrease in expenses related to atebimetinib due to the timing of expenses related to the initiation of the MAPKeeper 301 trial. The decrease to research and development expenses was offset by increased preclinical spend of approximately $0.8 million, driven by development pipeline activities, and by an increase in indirect expenses of approximately $0.2 million, primarily driven by increased employee-related costs of $0.3 million, further offset by stock-based compensation costs of $0.1 million, in addition to depreciation/amortization and facilities and other expenses of $5 thousand.
Current wording
Research and development expenses increased by approximately $3.5 million, or 33.9%, to approximately $14.0 million for the three months ended June 30, 2026, as compared to approximately $10.5 million for the three months ended June 30, 2025. The increase of approximately $3.5 million was primarily due to an increase in direct costs of $2.8 million, driven by $2.1 million related to the initiation of the MAPKeeper 301 trial, in addition to increased preclinical spend of approximately $1.0 million, driven by development pipeline activities. The increase in direct research and development expenses was offset by a decrease of approximately $0.3 million in expenses related to the envometinib program, due to the Company's prioritization of the atebimetinib program. The overall increase in research and development expenses was also driven by an increase in indirect expenses of approximately $0.7 million, primarily driven by increased employee-related costs of $0.7 million, increased stock-based compensation costs of $0.1 million, offset by a decrease in depreciation/amortization and facilities and other expenses of $1 thousand.
Previous wording
General and administrative expenses increased by approximately $0.7 million, or 16.9%, to approximately $4.7 million for the three months ended March 31, 2026, as compared to approximately $4.0 million for the three months ended March 31, 2025. The increase of approximately $0.7 million was primarily driven by a $0.4 million increase in employee-related costs, a $0.2 million increase in professional fees for accounting, auditing and legal services, and a $0.1 million increase in other expenses, stock-based compensation, and facilities and other allocated expenses, in the aggregate.
Current wording
General and administrative expenses increased by approximately $0.7 million, or 16.3%, to approximately $5.0 million for the three months ended June 30, 2026, as compared to approximately $4.3 million for the three months ended June 30, 2025. The increase of approximately $0.7 million was primarily driven by a $0.5 million increase in employee-related costs, a $0.1 million increase in other expenses, primarily consisting of increased software costs supporting the general and administrative functions, and a $0.1 million increase in professional fees, stock-based compensation, and facilities and other allocated expenses, in the aggregate.
Previous wording
Interest income from the interest earned on our cash, cash equivalents and marketable securities balances increased by approximately $0.9 million for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025, driven primarily by an increased total cash balance resulting from various financing events in August and September 2025.
Current wording
Interest income from the interest earned on our cash, cash equivalents and marketable securities balances increased by approximately $0.8 million for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025, driven primarily by an increased total cash balance resulting from various financing events in August and September 2025.
Previous wording
Other income for the three months ended March 31, 2026 was $0.5 million, compared to no other income for the three months ended March 31, 2025. This was primarily driven by the accretion of marketable securities during the three months ended March 31, 2026. There were no marketable securities as of March 31, 2025.
Current wording
Other income for the three months ended June 30, 2026 was $0.6 million, compared to no other income for the three months ended June 30, 2025. This was primarily driven by the accretion of marketable securities during the three months ended June 30, 2026. There were no marketable securities as of June 30, 2025.
Previous wording
As of March 31, 2026, we had an accumulated deficit of $293.8 million and $198.6 million in cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, reflected in the change in our outstanding accounts payable and accrued expenses.
Current wording
As of June 30, 2026, we had an accumulated deficit of $311.1 million and $182.7 million in cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are comprised primarily of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, reflected in the change in our outstanding accounts payable and accrued expenses.
Previous wording
On August 10, 2022, we entered into the 2022 Sales Agreement with the Sales Agent to sell shares of our common stock with aggregate gross proceeds of up to $50 million, from time to time, through the 2022 ATM Program. We did not sell any shares of common stock under the 2022 ATM Program during the three months ended March 31, 2026. We sold 4,836,804 shares of common stock under the 2022 ATM Program, at a weighted average price per share of $2.95, for aggregate gross proceeds of $14.2 million ($13.7 million net of offering expenses) during the three months ended March 31, 2025. In August 2025, the 2022 Shelf Registration Statement and the 2022 ATM Program expired, and the 2022 Sales Agreement was terminated.
Current wording
On August 10, 2022, we entered into the 2022 Sales Agreement with the Sales Agent to sell shares of our common stock with aggregate gross proceeds of up to $50 million, from time to time, through the 2022 ATM Program. We did not sell any shares of common stock under the 2022 ATM Program during the three and six months ended June 30, 2026. We sold 4,836,804 shares of common stock under the 2022 ATM Program, at a weighted average price per share of $2.95, for aggregate gross proceeds of $14.2 million ($13.7 million net of offering expenses) during the three and six months ended June 30, 2025. In August 2025, the 2022 Shelf Registration Statement and the 2022 ATM Program expired, and the 2022 Sales Agreement was terminated.
Previous wording
On August 13, 2025, we entered into the 2025 Sales Agreement with the Sales Agent, to sell shares of our common stock with aggregate gross proceeds of up to $100 million, from time to time, through the 2025 ATM Program. In connection with the September 2025 Offering, we: (i) reduced the maximum aggregate offering price for sales of shares of common stock pursuant to at-the-market transactions under the 2025 ATM Program by the Reduced Amount, resulting in a new maximum aggregate offering price of up to $98,749,993 under the 2025 ATM Program, and (ii) suspended the 2025 ATM Program and terminated the continuous offering under the 2025 ATM Program, in each case, as to the Reduced Amount. We did not sell any shares of common stock under the 2025 ATM Program during the three months ended March 31, 2026 or March 31, 2025, respectively.
Current wording
On August 13, 2025, we entered into the 2025 Sales Agreement with the Sales Agent, to sell shares of our common stock with aggregate gross proceeds of up to $100 million, from time to time, through the 2025 ATM Program. In connection with the September 2025 Offering, we: (i) reduced the maximum aggregate offering price for sales of shares of common stock pursuant to at-the-market transactions under the 2025 ATM Program by the Reduced Amount, resulting in a new maximum aggregate offering price of up to $98,749,993 under the 2025 ATM Program, and (ii) suspended the 2025 ATM Program and terminated the continuous offering under the 2025 ATM Program, in each case, as to the Reduced Amount. We did not sell any shares of common stock under the 2025 ATM Program during the three and six months ended June 30, 2026 or June 30, 2025, respectively.
Previous wording
As of March 31, 2026, we had contractual obligations related to various leases of $0.6 million for 2026, $0.8 million for 2027, $0.8 million for 2028, $0.8 million for 2029, $0.9 million for 2030 and $1.2 million for the periods thereafter.
Current wording
As of June 30, 2026, we had contractual obligations related to various leases of $0.4 million for 2026, $0.8 million for 2027, $0.8 million for 2028, $0.8 million for 2029, $0.9 million for 2030 and $1.2 million for the periods thereafter.
Previous wording
During the three months ended March 31, 2025, operating activities used approximately $14.1 million of cash, primarily resulting from our net loss of approximately $15.0 million and changes in assets and liabilities of $1.0 million, partially offset by stock-based compensation expense of approximately $1.7 million and the reduction in carrying amount of right-of-use assets of approximately $0.1 million.
Current wording
During the six months ended June 30, 2026, operating activities used approximately $34.9 million of cash, primarily resulting from our net loss of approximately $30.7 million, changes in assets and liabilities of $6.9 million, and accretion of discount of marketable securities of $0.9 million. This was partially offset by stock-based compensation expense of approximately $3.3 million, depreciation of approximately $0.2 million and the reduction in carrying amount of right-of-use assets of approximately $0.2 million.
Previous wording
During the three months ended March 31, 2026, operating activities used approximately $18.4 million of cash, primarily resulting from our net loss of approximately $13.5 million and changes in assets and liabilities of $6.4 million, partially offset by stock-based compensation expense of approximately $1.6 million, depreciation of approximately $0.1 million and the reduction in carrying amount of right-of-use assets of approximately $0.1 million.
Current wording
During the six months ended June 30, 2025, operating activities used approximately $23.5 million of cash, primarily resulting from our net loss of approximately $29.5 million and changes in assets and liabilities of $2.4 million, partially offset by stock-based compensation expense of approximately $3.2 million, depreciation of approximately $0.2 million and the reduction in carrying amount of right-of-use assets of approximately $0.2 million.
Previous wording
During the three months ended March 31, 2026, investing activities used approximately $63.1 million of cash, primarily resulting from purchases of marketable securities of $72.0 million and purchases of property and equipment of approximately $80 thousand, offset by maturities of marketable securities of $9.0 million.
Current wording
During the six months ended June 30, 2026, investing activities used approximately $52.6 million of cash, primarily resulting from purchases of marketable securities of $84.0 million and purchases of property and equipment of approximately $0.1 million, offset by maturities of marketable securities of $31.5 million.
Previous wording
During the three months ended March 31, 2025, investing activities used approximately $9 thousand, primarily resulting from purchases of property and equipment of approximately $9 thousand.
Current wording
During the six months ended June 30, 2025, investing activities used approximately $11 thousand, primarily resulting from purchases of property and equipment of approximately $11 thousand.
Previous wording
During the three months ended March 31, 2026, net cash provided by financing activities was approximately $0.2 million, primarily driven by proceeds of approximately $0.2 million from the sale of common stock pursuant to our employee stock purchase plan and $10 thousand from the exercise of stock options.
Current wording
During the six months ended June 30, 2026, net cash provided by financing activities was approximately $0.2 million, primarily driven by proceeds of approximately $0.2 million from the sale of common stock pursuant to our employee stock purchase plan and $35 thousand from the exercise of stock options.
Previous wording
During the three months ended March 31, 2025, net cash provided by financing activities was approximately $13.8 million, primarily driven by proceeds of approximately $13.7 million from the sale of common stock under our 2022 ATM program, net of offering expenses, in addition to $0.1 million from the sale of common stock pursuant to our employee stock purchase plan.
Current wording
During the six months ended June 30, 2025, net cash provided by financing activities was approximately $13.7 million, primarily driven by proceeds of approximately $13.7 million from the sale of common stock under the 2022 ATM Program, net of issuance costs, in addition to $0.2 million from the Company's employee stock purchase plan and exercise of stock options. This was partially offset by payments of offering costs of $0.1 million
Previous wording
•the costs and results of our ongoing clinical trial for atebimetinib, our planned registrational trial of atebimetinib in combination with mGnP in first-line pancreatic cancer, and potential future clinical trials for atebimetinib and our other product candidates;
Current wording
•the costs and results of our ongoing clinical trials for atebimetinib, and potential future clinical trials for atebimetinib and our other product candidates;
Previous wording
Based on our currently forecasted operating plan, we believe that our existing cash, cash equivalents and marketable securities as of March 31, 2026 will enable us to fund our operating expenses and capital expenditure requirements into 2029. Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future and the need to raise additional capital to finance future operations, as of May 15, 2026, the issuance date of the interim condensed consolidated financial statements for the three-months ended March 31, 2026 included elsewhere in this Quarterly Report on Form 10-Q, management considered whether or not there are conditions or events, in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern, and concluded that there are none as it estimates that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of these unaudited condensed consolidated financial statements.
Current wording
Based on our currently forecasted operating plan, we believe that our existing cash, cash equivalents and marketable securities as of June 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements into 2029. Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future and the need to raise additional capital to finance future operations, as of August 5, 2026, the issuance date of the interim condensed consolidated financial statements for the three and six-months ended June 30, 2026 included elsewhere in this Quarterly Report on Form 10-Q, management considered whether or not there are conditions or events, in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern, and concluded that there are none as it estimates that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of these unaudited condensed consolidated financial statements.
Rearranged current paragraphs (5)
Current report — wording carried from elsewhere
•in the second half of 2026, dosing the first patient in a clinical trial of atebimetinib in combination with Libtayo® in non-small cell lung cancer patients, with a preliminary data readout expected in late-2027;
Current report — wording carried from elsewhere
The following table summarizes our results of operations for the periods indicated:
Current report — wording carried from elsewhere
Amortization of intangible asset was $14,633 for the six months ended June 30, 2026, and 2025. This amortization is related to the technology acquired for the BioArkive acquisition completed in December 2021.
Current report — wording carried from elsewhere
Interest income increased by approximately $1.7 million for the six months ended June 30, 2026, compared to the six months ended June 30, 2025, driven primarily by an increased total cash balance resulting from various financing events in August and September 2025.
Current report — wording carried from elsewhere
Other income for the six months ended June 30, 2026 was approximately $1.2 million, compared to no other income for the six months ended June 30, 2025. This was primarily driven by the accretion of marketable securities during the six months ended June 30, 2026. There were no marketable securities as of June 30, 2025.